PL2477628T3 - Wytwarzanie krystalicznych hemihydratowych postaci dihydropirazolopirymidynonu - Google Patents

Wytwarzanie krystalicznych hemihydratowych postaci dihydropirazolopirymidynonu

Info

Publication number
PL2477628T3
PL2477628T3 PL10817669T PL10817669T PL2477628T3 PL 2477628 T3 PL2477628 T3 PL 2477628T3 PL 10817669 T PL10817669 T PL 10817669T PL 10817669 T PL10817669 T PL 10817669T PL 2477628 T3 PL2477628 T3 PL 2477628T3
Authority
PL
Poland
Prior art keywords
dihydropyrazolopyrimidinone
preparation
crystalline hemihydrate
hemihydrate forms
forms
Prior art date
Application number
PL10817669T
Other languages
English (en)
Inventor
Rositza Petrova
Eric Sirota
Robert Wenslow
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PL2477628T3 publication Critical patent/PL2477628T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL10817669T 2009-09-15 2010-09-02 Wytwarzanie krystalicznych hemihydratowych postaci dihydropirazolopirymidynonu PL2477628T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24242809P 2009-09-15 2009-09-15
US32304510P 2010-04-12 2010-04-12
EP10817669.4A EP2477628B1 (en) 2009-09-15 2010-09-02 Preparation of crystalline hemihydrate forms of dihydropyrazolopyrimidinone
PCT/US2010/047622 WO2011034743A1 (en) 2009-09-15 2010-09-02 Preparation of crystalline forms of dihydropyrazolopyrimidinone

Publications (1)

Publication Number Publication Date
PL2477628T3 true PL2477628T3 (pl) 2015-02-27

Family

ID=43758964

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10817669T PL2477628T3 (pl) 2009-09-15 2010-09-02 Wytwarzanie krystalicznych hemihydratowych postaci dihydropirazolopirymidynonu

Country Status (9)

Country Link
US (2) US8703779B2 (pl)
EP (1) EP2477628B1 (pl)
DK (1) DK2477628T3 (pl)
ES (1) ES2524161T3 (pl)
HR (1) HRP20140821T1 (pl)
PL (1) PL2477628T3 (pl)
PT (1) PT2477628E (pl)
SI (1) SI2477628T1 (pl)
WO (1) WO2011034743A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013039854A1 (en) 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
JP6717457B2 (ja) 2017-01-23 2020-07-01 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Wee1阻害剤としての1,2−ジヒドロ−3H−ピラゾロ[3,4−d]ピリミジン−3−オン誘導体
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
SG11202003974XA (en) 2017-11-01 2020-05-28 Shijiazhuang Sagacity New Drug Development Co Ltd Macrocyclic compound serving as weel inhibitor and applications thereof
US12180184B2 (en) 2018-10-26 2024-12-31 Wuxi Biocity Biopharmaceutics Co., Ltd. Pyrimidopyrazolone derivative as Wee1 inhibitor and use thereof
JP2022526831A (ja) 2019-04-09 2022-05-26 ニューベイション・バイオ・インコーポレイテッド ヘテロ環式化合物およびその使用
SI3964510T1 (sl) 2019-04-30 2024-10-30 Wuxi Biocity Biopharmaceutics Co., Ltd. Kristalna oblika WEE1 inhibitorske spojine in njena uporaba
EP4048277A1 (en) 2019-10-25 2022-08-31 Astrazeneca AB Methods of treating cancer
CA3165477A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
US20230065577A1 (en) * 2019-12-20 2023-03-02 Recurium Ip Holdings, Llc Combinations
CA3180664A1 (en) 2020-06-17 2021-12-23 Yuli Xie Pyrazolo[3,4-d]pyrimidine-3-one derivative as wee-1 inhibitor
KR20240004539A (ko) 2021-04-30 2024-01-11 위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드 Wee-1 억제제로서의 축합 고리 화합물, 그를 위한 제조 방법 및 그의 용도
CN113735863A (zh) * 2021-09-29 2021-12-03 武汉九州钰民医药科技有限公司 Wee1抑制剂adavosertib的制备工艺
CN113880844B (zh) * 2021-09-29 2023-02-14 武汉九州钰民医药科技有限公司 Wee1蛋白激酶抑制剂adavosertib的化学合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091255A1 (en) 2002-04-26 2003-11-06 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
JP5411847B2 (ja) 2007-04-25 2014-02-12 Msd株式会社 Weelキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形

Also Published As

Publication number Publication date
US8703779B2 (en) 2014-04-22
EP2477628A4 (en) 2013-04-17
US20140187562A1 (en) 2014-07-03
EP2477628A1 (en) 2012-07-25
PT2477628E (pt) 2014-11-25
EP2477628B1 (en) 2014-08-20
WO2011034743A1 (en) 2011-03-24
US20120172370A1 (en) 2012-07-05
HRP20140821T1 (hr) 2014-10-10
US9388186B2 (en) 2016-07-12
SI2477628T1 (sl) 2014-11-28
DK2477628T3 (en) 2014-11-24
ES2524161T3 (es) 2014-12-04

Similar Documents

Publication Publication Date Title
PL2477628T3 (pl) Wytwarzanie krystalicznych hemihydratowych postaci dihydropirazolopirymidynonu
IL216648A0 (en) Crystalline forms of febuxostat
IL209196A (en) A crystalline form of posaconazole
EP2435390A4 (en) TRANSALCYLATION OF POLYCYCLOHEXYLBENZENES
PL2401244T3 (pl) Sposoby produkcji ceramicznych struktur
ZA201105045B (en) Crystalline forms of genistein
EP2424845A4 (en) PREPARATION OF DECITABIN
ZA201109045B (en) Crystalline form of pemirolast
ZA201202097B (en) Crystalline forms of substituted pyrazolopyrimidines
ZA201204108B (en) Crystalline forms of bosentan salts and processes for their preparation
GB0908711D0 (en) Preparation of labelled compounds
GB0922023D0 (en) Preparation of n-monofluoroalkyl compounds
PT2655363T (pt) Formas cristalinas e processos para a sua preparação
EP2459540A4 (en) PREPARATION OF FIPAMEZOLE
IL205857A0 (en) Processes for preparation of crystalline tigecyclline form ii
GB2470249B (en) Preparation of coverings
EP2404891A4 (en) PROCESS FOR THE PREPARATION OF ACYLBENZENES
PL2408799T3 (pl) Nowa krystaliczna postać anty-progesteronu CDB-4124
EP2331490A4 (en) PREPARATION OF DIBUTOXYMETHANE
SI2504309T1 (sl) Sinteza acetokslacetaldehida
IL195092A0 (en) Crystalline form of (s)-1-phenylethylammonium (r)-diphenyl-methanesulphinyl-acetate
GB201301307D0 (en) Crystalline form of prulifloxacin and processes for its preparation
TWM372743U (en) Improved structure of Kendama
TWM365675U (en) Improved structure of teapoy
SI2398784T1 (sl) Kristalna oblika febuksostata